David Segarra active positions
| Companies | Position | Start | End |
|---|---|---|---|
AptaTargets SL
 AptaTargets SL Pharmaceuticals: MajorHealth Technology AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then. | Director/Board Member | 01/01/2014 | - |
| Chief Executive Officer | 01/01/2014 | - | |
| Founder | 01/01/2014 | - |
Career history of David Segarra
Former positions of David Segarra
| Companies | Position | Start | End |
|---|---|---|---|
Aptus Biotech SL
 Aptus Biotech SL BiotechnologyHealth Technology Aptus Biotech SL develops drug candidates using its aptamer platform. It is a biotechnology company specializing in the development and customization of Aptamers fully adapted to the needs of each application. The firm’s product Aptateca, offers a catalog of aptamers. The company was founded by David Segarra and María Eugenia Zarabozo in 2010 and is headquartered in Madrid, Spain. | Chief Executive Officer | 01/01/2010 | - |
| Founder | 01/01/2010 | - |
Statistics
International
| Spain | 3 |
Operational
| Chief Executive Officer | 2 |
| Founder | 2 |
| Director/Board Member | 1 |
Sectoral
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Aptus Biotech SL
Aptus Biotech SL BiotechnologyHealth Technology Aptus Biotech SL develops drug candidates using its aptamer platform. It is a biotechnology company specializing in the development and customization of Aptamers fully adapted to the needs of each application. The firm’s product Aptateca, offers a catalog of aptamers. The company was founded by David Segarra and María Eugenia Zarabozo in 2010 and is headquartered in Madrid, Spain. | Health Technology |
AptaTargets SL
AptaTargets SL Pharmaceuticals: MajorHealth Technology AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then. | Health Technology |
- Stock Market
- Insiders
- David Segarra
- Experience
